Li Shengbiao, Zhang Yi, Zhang Tianyi, Jiang Donghui, Li Mi, Chen Ligang, Jiang Jun, Zhang Chunxiang, Li Qiuhong
School of Basic Medical Sciences, Southwest Medical University, No. 1 Section 1, Xianglin Road, Longmatan District, Luzhou, 646000, Sichuan, China.
Department of Cardiology, The Affiliated Hospital of Southwest Medical University, Key Laboratory of Medical Electrophysiology, Ministry of Education, Institute of Cardiovascular Research, Basic Medicine Research Innovation Center for Cardiometabolic Diseases, Ministry of Education, Nucleic Acid Medicine of Luzhou Key Laboratory, Southwest Medical University, Luzhou, 646000, Sichuan, China.
In Vitro Cell Dev Biol Anim. 2025 Mar;61(3):311-319. doi: 10.1007/s11626-024-01005-y. Epub 2025 Jan 13.
Atherosclerosis (AS) is a prevalent cardiovascular condition, and the growth and phenotypic switch of vascular smooth muscle cells (VSMCs) play a crucial role in its development. Studies have revealed that the activation of certain transcription factors and signaling pathways can trigger these cellular changes. Consequently, targeting these pathways and pivotal molecules has emerged as a promising strategy for AS treatment. Drugs that can reverse the cellular changes in VSMCs may offer new therapeutic options for AS, marking a significant advancement. While previous research has suggested that urolithin B (Uro B) possesses anti-atherosclerotic properties, its exact mechanism remains to be fully understood, especially the effect of Uro B in VSMCs. This study discovered that Uro B can impede the proliferation and migration of VSMCs prompted by PDGF-BB, as well as their phenotypic changes, indicating that Uro B could potentially prevent AS by inhibiting the phenotypic switch of VSMCs.
动脉粥样硬化（AS）是一种常见的心血管疾病，血管平滑肌细胞（VSMC）的生长和表型转换在其发展过程中起着关键作用。研究表明，某些转录因子和信号通路的激活可引发这些细胞变化。因此，针对这些通路和关键分子已成为一种有前景的AS治疗策略。能够逆转VSMC细胞变化的药物可能为AS提供新的治疗选择，这标志着一项重大进展。虽然先前的研究表明尿石素B（Uro B）具有抗动脉粥样硬化特性，但其确切机制仍有待充分了解，尤其是Uro B对VSMC的影响。本研究发现，Uro B可抑制PDGF-BB诱导的VSMC增殖、迁移及其表型变化，表明Uro B可能通过抑制VSMC的表型转换来预防AS。
